


THE PIH GUIDE TO

Chronic Care Integration for Endemic Non-Communicable Diseases

RWANDA EDITION

CARDIAC, RENAL, DIABETES, PULMONARY, AND PALLIATIVE CARE



Partners In Health

Harvard Medical School

Department of Global Health and Social Medicine

Program in Global Non-Communicable Disease and Social Change

Brigham and Women's Hospital


Division of Global Health Equity

THE PIH GUIDE TO

Chronic Care Integration for Endemic Non-Communicable Diseases

RWANDA EDITION

CARDIAC, RENAL, DIABETES, PULMONARY, AND PALLIATIVE CARE



Partners In Health

Harvard Medical School

Department of Global Health and Social Medicine

Program in Global Non-Communicable Disease and Social Change

Brigham and Women's Hospital

Division of Global Health Equity



.....

Jeanette Niyonsaba died from rheumatic heart disease at the age of fourteen. Jeanette fought her disease with bravery and determination. This guide is dedicated to her memory.

.....

About the Cover

Butaro District Hospital is a 150-bed public facility that sits on a mountaintop in northern Rwanda's Burera District. In addition to serving the district's 350,000 people, the majority of whom still survive on about a dollar a day, Butaro will also serve as a national teaching hospital and clinical center of excellence. Led by Partners In Health, in collaboration with the Rwandan government, the hospital was built by 3500 men and women from the local community using local materials. This world-class facility was inaugurated on January 24th, 2011. At the inauguration ceremony, Rwandan President Paul Kagame said, "Butaro is more than a hospital. It is a unique story of exceptional people with the desire to see positive change in the world and in communities like the one hosting us today. ... It is also a story about strong and mutually benefiting partnerships and the fact that when we come together and join forces, commendable results can be achieved."

In the years to come, Rwandan clinical leaders based at this flagship teaching hospital will train the next generation of nurses and physicians tackling the long tail of endemic non-communicable disease throughout Rwanda, and the world.

PHOTO CREDIT: Matthew Craven and Peter Drobac

CONTRIBUTORS AND ACKNOWLEDGEMENTS

Editors-in-Chief

Gene Bukhman, MD, PhD

Alice Kidder, MD, MPH

Principal Authors

Alice Kidder, MD, MPH

Gene Kwan, MD

Corrado Cancedda, MD, PhD

Gene Bukhman, MD, PhD

Special Contributors

Eric Krakauer, MD, PhD (Chapter 2: Palliative Care)

Joseph Mucumbitsi, MD and Ralph Morton Bolman III, MD
(Chapter 5: Cardiac Surgery)

Andrea Braun, MD and Sharon Su, MD (Chapter 6: Renal Failure)

Charlotte Bavuma, MD and Anand Vaidya, MD (Chapter 7: Diabetes)

Nancy Lange, MD and Sanctus Musafiri, MD
(Chapter 10: Chronic Respiratory Disease)

Vanessa Wolfman, MD, MPH and Sara Stulac, MD (Pediatric Content)

Contributors

Patrick Almazor, Cheryl Amoroso, Ellen Ball, Amy Banham, Anne Beckett, Didi Bertrand Farmer, Agnes Binagwaho, Gilbert Biraro, Corrado Cancedda, Chadi Cortas, Jonathan Crocker, Maros Cunderlik, Felix Cyamatare, Peter Drobac, Symaque Dusabeyezu, Henry Epino, Paul Farmer, Ildephonse Fayida, Hamish Fraser, Bonnie Frawley, Amber Gaumnitz, Jill Hackett, Christiane Haeffele, Emily Hall, Michael Herce, Lisa Hirschhorn, Louise Ivers, Darius Jazayeri, Waking Jean-Baptiste, Joanel Joasil, Keith Joseph, Jules Kabahizi, Emmanuel Kamanzi, Shashi Kants, Vanessa Kerry, Salmaan Keshavjee, Tracy Kidder, Frances Kidder, Felicia Knaul, Meera Kotagal, Mike Landzberg, Patrick Lee, Jennifer Lewey, Natalie Lorent, Alishya Mayfield, Joia Mukherjee, Megan Murray, Emmanuel Musbeyezu, Francis Mutabazi, Cadet Mutumbira, Gedeon Ngoga, Jean Paul Ngiuwera, Victor Nkulikiyinka, Emilen Nkusi, Joseph Ntarindwa, Fabrice Usenga, Alice Nyirimana, Bonaventure Nzeyimana, Daniel Palazuelos, Lindsay Palazuelos, Manisha Patel, Ceeya Patton-Bolman, Giuseppe Raviola, James Rawn, Michael Rich, Robert Riviello, Elizabeth Riviello, Jean Louis Romain, Valens Rudakubana, Emmanuel Rusingiza Kamanzi, Jacklin Saint-Fleur, Sachita Shah, Aaron Shakow, Lawrence Shulman, Amy Sievers, Neo Tapela,

Kate Thorson, Mariam Uwase, Anand Vadivel, Ashwin Vasan, Loune Viaud, Alexandra Vinograd, David Walton, Charlotte Wu, Justin Zachariah.

Acknowledgements

We would like to thank the following reviewers for their comments on parts of this text at an earlier stage in its development: Ana Olga Mocumbi (Chapter 4: Heart Failure), Geoffrey Gill and John Yudkin (Chapter 7: Diabetes), Bongani Mayosi (Chapter 9: Rheumatic Heart Disease Prevention). We would like to thank Tracy Kidder for his editorial assistance. We thank the Doris Duke Charitable Foundation for implementation support for the handbook use.

We particularly wish to thank the Rwandan Ministry of Health for its exceptional leadership and support, as well as the people of Rwanda who continually inspire us.

This project was funded through a grant from the Medtronic Foundation to Partners In Health.

Copyright © 2011 Partners In Health. All rights reserved under International and Pan-American Copyright Conventions

Design: Flanders + Associates

ISBN: 978-0-6154548-9-4

NOTICE

This guide was designed for use by advanced nurses, clinical officers, physicians, and policy makers dealing with endemic non-communicable diseases in rural Rwanda and similar settings. The chronic care integration guide has been prepared by Partners In Health with the assistance of various contributors and authors, including, without limitation, each of the following parties: the Department of Global Health and Social Medicine, Harvard Medical School; the Division of Global Health Equity, Brigham and Women's Hospital; and each of their affiliates, divisions, directors, officers, trustees, agents and employees (collectively, with Partners In Health, the "Contributors and Authors"), for general informational purposes only. It is not intended as and should not be regarded or relied upon as medical advice or opinion, or as a substitute for the advice of a medical practitioner. You should not rely on, take any action or fail to take any action based upon the chronic care integration guide.

Mention of specific drugs or products within the guide does not constitute endorsement by any of the above-named individuals or entities. With regard to specific drugs or products, medical practitioners are advised to consult their normal resources before prescribing to their patients.

Every possible effort has been made to ensure that the material presented herein is accurate, reliable, and in accord with current standards, but none of the contributors and authors represents or warrants that the information contained herein is complete or accurate or free from error. Wherever possible, the material has been harmonized with clinical algorithms currently employed by the national ministry of health. However, as new research and experience expand our knowledge and geographic reach, recommendations for care and treatment will change accordingly. As such, it is the responsibility of the individual clinician to use his/her best medical judgment in determining appropriate care and treatment based on individual patient needs, as well as relevant guidelines and constraints of the country and facility in which he/she works.

As between Partners In Health and you, Partners In Health or its licensors at all times owns and retains all right, title and interest in and to the chronic care integration guide, including all intellectual property rights therein and thereto. You may use and copy the chronic care integration guide, or portions of the guide, provided that you (i) promptly notify Partners In Health via email at harvardncd@pih.org of any such use; and (ii) reproduce all copyright notices, claims or reservation of rights appearing on the chronic care guide, as delivered to you, on all copies made pursuant to this sentence.

To the maximum extent permitted under applicable laws, none of the Contributors and Authors are liable, under any circumstance or under any theory of law, tort, contract, strict liability or otherwise, for any direct, indirect, special, incidental, consequential, exemplary or punitive damages, or any other injury and/or damage (actual or perceived), including, without limitation, damages based on errors, omissions, or reliance upon, use, or operation of any ideas, instructions, procedures, products, or methods contained in the material included in this guide.

By using this guide, you acknowledge and agree to the terms of this notice.

TABLE OF CONTENTS

FOREWORD 1

Agnes Binagwaho

xxiii

FOREWORD 2

Bongani Mayosi

xxvii

ABBREVIATIONS

xxix

CHAPTER 1

Integration of Chronic Care Services in Rwanda

1

1.1	The Long Tail of Endemic Non-Communicable Diseases in Rwanda	1
1.2	A Framework for Strategic Planning for Endemic Non-Communicable Disease	4
1.3	Decentralization and Integration of Chronic Care for Non-Communicable Disease in Rwanda	6
1.4	Which Chronic Diseases?	7
1.5	The District Hospital as a Source of Clinical Leadership	7
1.6	District Inpatient Care	10
1.7	Health Centers: Case Finding, Initial Management, and Chronic Care	10
1.8	Referral Centers	11
1.9	Out-of-Country Referral	12
1.10	Screening	12
1.11	Principles of Patient Follow-Up and Retention: Community Health Workers and the Electronic Medical Record	12
1.12	Equipment, Medication Procurement, and Costs	13
	Chapter 1 References	14

CHAPTER 2

Palliative Care and Chronic Care

17

2.1	History and Philosophy of Palliative Care Efforts in Resource-Poor Settings	18
2.2	Community Health Workers and Common Palliative Care Interventions in the Treatment of Chronic Disease	19
2.2.1	Assessment of Symptoms	20
2.2.2	Symptom Management	21
2.2.3	Pain	22
2.2.3.1	Nociceptive Pain	22
2.2.3.2	Neuropathic Pain	22

2.2.3.3	Principles of Pain Management	23
2.2.4	Dyspnea	27
2.2.5	Nausea/Vomiting	27
2.2.6	Constipation	29
2.2.7	Diarrhea	29
2.2.8	Delirium/Agitation	30
2.2.9	Pruritus and Pressure Ulcers	30
2.2.10	Giving Bad News	32
2.2.11	Psychosocial and Spiritual Issues	32
Chapter 2 References		33

CHAPTER 3

Role of Community Health Workers, Family Planning, Mental Health, Pharmacy, Laboratory, and Social Services in the Treatment of Chronic Disease

3.1	Community Health Workers	35
3.2	Housing Assistance	36
3.3	Nutritional Support	37
3.4	Mental Health	37
3.5	Family Planning in Chronic Disease	37
3.6	Pharmacy Services	38
3.7	Laboratory	39
3.8	Other Diagnostic Equipment	39
Chapter 3 References		41

CHAPTER 4

Heart Failure

4.1	Defining Categories of Heart Failure	45
4.2	Physical Exam Findings for Classification of Heart Failure	47
4.3	Echocardiography for Classification of Heart Failure	48
4.3.1	The Parasternal Long Axis View	48
4.3.2	The Subcostal View	50
4.3.3	Ejection Fraction and Fractional Shortening	53
4.3.4	Assessment for Mitral Stenosis	54
4.3.5	Assessment of Right Heart Size	55
4.3.6	Assessment of the Inferior Vena Cava	56
4.3.7	Assessment of Pericardial Effusion	56
4.4	Initial Recognition and Referral of the Heart Failure Patient	57
4.5	Heart Failure Severity Classification	62
4.6	Decompensated Heart Failure	62
4.7	Fluid Status Assessment	65
4.7.1	Guidelines for Initiating Intravenous Diuresis	69

4.7.2	Guidelines for Initiating and Titrating Oral Furosemide at Health-Center Level	70
4.7.3	Guidelines for Use of Other Diuretics	71
4.7.3.1	Spironolactone	71
4.7.3.2	Hydrochlorothiazide	71
4.7.4	Dangers of Diuresis	71
4.8	Cardiomyopathy	72
4.8.1	Vital Sign Assessment	74
4.8.2	Fluid Status Assessment	74
4.8.3	Titration of Mortality-Reducing Medications	74
4.8.3.1	Beta-Blockers in Heart Failure	77
4.8.3.2	ACE Inhibitors	78
4.8.3.3	Hydralazine and Isosorbide Dinitrate	79
4.8.3.4	Spironolactone	80
4.8.4	Other Medications in Cardiomyopathy Management	81
4.8.4.1	Digoxin (Digitalis)	83
4.8.4.2	Aspirin	83
4.8.4.3	Birth Control	83
4.8.4.4	Antiretrovirals (ARVs)	84
4.9	Hypertensive Heart Disease Etiology and Diagnosis	84
4.9.1	Vital Sign Assessment	85
4.9.2	Fluid Status Assessment	85
4.9.3	Titration of Antihypertensives	86
4.10	Mitral Stenosis	88
4.10.1	Vital Sign Assessment	90
4.10.2	Fluid Status Assessment	90
4.10.3	Control of Heart Rate	90
4.10.4	Other Medications in Management of Mitral Stenosis	91
4.10.4.1	Penicillin	91
4.10.4.2	Birth Control	91
4.10.4.3	Anticoagulation (Aspirin and Warfarin)	91
4.11	Other Valvular and Congenital Heart Disease	91
4.11.1	Vital Sign Assessment	93
4.11.2	Fluid Status Assessment	93
4.11.3	Titration of ACE Inhibitors	94
4.11.4	Other Medications	95
4.11.4.1	Spironolactone	95
4.11.4.2	Penicillin	96
4.11.5	Cardiac Surgery Evaluation	97
4.12	Isolated Right-Sided Heart Failure Etiology and Diagnosis	98
4.12.1	Vital Sign Assessment	100
4.12.2	Fluid Status Assessment	101
4.12.3	Pericardial Disease	102
4.12.3.1	Pericardial Effusions	102
4.12.3.2	Constrictive Pericarditis	102

4.12.3.3	Diagnosis and Treatment of Tuberculosis Pericarditis	102
4.12.4	Titration of ACE Inhibitors and Spironolactone and Paracentesis	104
4.12.5	Other Medication Needs	105
4.13	Heart Failure Patient Follow-Up	106
4.14	Potassium Management	107
4.15	Arrhythmia Diagnosis and Management	107
4.16	Role of Electrocardiography in Rural Rwanda	107
4.16.1	Atrial Fibrillation Diagnosis and Management	108
4.17	Cardioversion	110
4.18	Palpitations and Somatization	111
4.19	Palliative Care for Patients with Heart Failure	113
	Chapter 4 References	115

CHAPTER 5

	Cardiac Surgery Screening, Referral, Anticoagulation, and Postoperative Management	119
5.1	History of Cardiac Surgery in Rwanda	119
5.1.1	Out-of-Country Referral to External Cardiac Surgical Centers	121
5.1.1.1	Philanthropic Centers	121
5.1.1.2	Fee-for-Service Centers	122
5.1.2	Visiting Cardiac Surgical Teams	122
5.2	Building a National Cardiac Surgery Program	123
5.2.1	Cardiac Surgical Referral	123
5.2.2	Principles of Case Selection	125
5.3	Common Procedures for Cardiac Valves	126
5.3.1	Mitral or Tricuspid Valve Repair	127
5.3.2	Percutaneous Procedures	128
5.3.3	Mechanical Valves	128
5.3.4	Bioprosthetic Valves	129
5.4	Early Post-Operative Evaluation (First 3 Months)	129
5.4.1	Heart Failure	130
5.4.2	Sternal Wound Infection and Dehiscence	130
5.4.3	Pericardial Tamponade	131
5.4.4	Endocarditis	131
5.4.5	Atrial Arrhythmias	131
5.5	Ongoing Monitoring of the Post-Operative Patient	132
5.5.1	Fever in Patients with Prosthetic Heart Valves	132
5.5.2	Valve Thrombosis	135
5.5.3	Valve Dehiscence	136

5.6	Penicillin Prophylaxis for Patients with Surgically Corrected Rheumatic Valvular Disease	136
5.7	Methods of Anticoagulation and Indications	136
5.8	Initiating Warfarin Therapy	138
5.8.1	Contraindications to Warfarin Therapy	138
5.8.2	Monitoring Warfarin	139
5.9	Titrating Warfarin Therapy	141
5.10	Drug Supply and Patient Monitoring	143
5.11	Dangers of Anticoagulation	144
	Chapter 5 References	145

CHAPTER 6

Chronic Kidney Disease 147

6.1	Etiology of Chronic Kidney Disease in Rural Rwanda	147
6.2	Screening for Renal Failure in High-Risk Populations	148
6.2.1	Hypertension	148
6.2.2	Diabetes	148
6.2.3	HIV	149
6.3	Classification of Renal Failure	150
6.4	Initial Evaluation and Management of Chronic Kidney Disease (CKD)	152
6.5	Hyperkalemia	158
6.6	Palliative Care for Chronic Kidney Disease	160
6.7	Renal Replacement Therapy (Hemodialysis and Peritoneal Dialysis)	162
6.8	Renal Transplantation	163
6.9	Acute Kidney Failure in Hospitalized Patients	163
	Chapter 6 References	164

CHAPTER 7

Diabetes 167

7.1	Opportunistic Identification and Screening for Diabetes in Acute Care Health Center Clinics	169
7.2	Recognition and Treatment of Emergency States (Hyperglycemia and Hypoglycemia)	172
7.2.1	Hyperglycemia	172
7.2.2	Hypoglycemia	174
7.3	Principles and Initial Management of Diabetes	175
7.3.1	Oral Hypoglycemic Agents	176
7.3.2	Patient Education	178
7.4	Management of Diabetes with Insulin Therapy	179
7.4.1	Initiation of Insulin Therapy	182

7.4.2	Insulin Regimen Selection	182
7.5	Insulin Use in the Community	185
7.5.1	Principles of Insulin Adjustment	187
7.6	Adjuvant Therapies and Routine Monitoring for Complications in Patients with Diabetes	191
7.7	Diabetes and Pregnancy	193
7.8	Social Assistance and Community Health Workers	194
7.8.1	Community Health Workers and Accompaniment	194
7.8.2	Food Assistance	194
	Chapter 7 References	196

CHAPTER 8

Hypertension 201

8.1	Clinic and Community-Based Hypertension Screening	203
8.1.1	Evaluation of Blood Pressure in Acute Care Clinics	206
8.1.2	Identification and Treatment of Emergency Conditions in Acute Consultation	206
8.1.3	Treatment of Asymptomatic Hypertension by Disease Classification	206
8.1.3.1	Stage 2 Hypertension (160/100–179/109 mmHg)	206
8.1.3.2	Stage 1 Hypertension (140/90–159/99) with High-Risk Features	207
8.1.3.3	Low-Risk Stage 1 Hypertension	207
8.2	Initial Management of Newly Referred Adult Hypertension Cases in Health Center Integrated Chronic Care Clinics	208
8.2.1	Identification and Treatment of Emergency Conditions in the Health Center Integrated Chronic Care Clinic	209
8.2.2	Evaluation for Comorbid Conditions in the Health Center Integrated Chronic Care Clinic	209
8.2.3	Evaluation of Hypertension Stage in the Health Center Integrated Chronic Care Clinic	210
8.2.3.1	Treatment of Higher-Risk Stage 1 Hypertension in the Health Center Integrated Chronic Care Clinic	210
8.2.3.2	Evaluation of Proteinuria in Stage 2 and Stage 3 Hypertension in the Health Center Integrated Chronic Care Clinic	210
8.2.3.3	Evaluation of Glycosuria in Stage 2 and Stage 3 Hypertension or Overweight Patients in the Health Center Integrated Chronic Care Clinic	210
8.2.3.4	Treatment of Stage 2 Hypertension in the Health Center Integrated Chronic Care Clinic	211
8.2.3.5	Treatment of Asymptomatic Stage 3 Hypertension in the Health Center Integrated Chronic Care Clinic	211

8.3	Recommended Hypertension Medications and Dosing	212
8.4	Recognition and Management of Hypertensive Emergency in Adults	214
8.5	Renal Dysfunction in Hypertension	215
8.5.1	Proteinuria or Mild to Moderate Renal Failure (Creatinine between 100–199 $\mu\text{mol/L}$)	216
8.6	Evaluation and Management of Hypertension in Patients ≥ 15	218
8.7	Follow-Up Treatment for Hypertension in Adults	220
8.7.1	Management of Well-Controlled Hypertension on Follow-Up	221
8.7.2	Follow-Up of Stage 1 Hypertension	221
8.7.3	Follow-Up of Stage 2 Hypertension	221
8.7.4	Follow-Up of Stage 3 Hypertension	221
8.8	Diagnosis and Management of Hypertension in Children (Age < 15)	221
8.8.1	Initial Diagnosis of Hypertension in Children	222
8.8.2	Recognition and Management of Hypertensive Emergency in Children	224
8.8.3	Initial Management of Children with Hypertension	224
8.8.4	Follow-Up of Children with Hypertension	225
8.8.5	Management of Hypertension in Children with Renal Failure	227
8.9	Hypertension in Pregnancy	228
8.9.1	Hypertension in Early Pregnancy (Chronic Hypertension)	232
8.9.2	Hypertension in Later Pregnancy (Gestational Hypertension and Preeclampsia)	232
8.9.3	Recognition and Management of Emergent Conditions	232
8.9.4	Screening for Preeclampsia	233
8.9.5	Treatment of Preeclampsia According to Disease Classification	233
8.9.5.1	Mild to Moderate Preeclampsia	234
8.9.5.2	Mild to Moderate Gestational Hypertension	234
	Chapter 8 References	236

CHAPTER 9

Rheumatic Heart Disease Prevention 239

9.1	Prevention of Acute Rheumatic Fever: Management of Sore Throat	239
9.2	Preventing Rheumatic Heart Disease: Management of Acute Rheumatic Fever and Secondary Prophylaxis for Rheumatic Fever	244
9.2.1	Acute Rheumatic Fever: Diagnosis and Follow-Up	245
9.3	Rheumatic Heart Disease Screening	247
9.3.1	Echocardiographic Screening for Rheumatic Heart Disease	248

9.3.2	Studies of RHD Prevalence	249
	Chapter 9 References	253

CHAPTER 10

Chronic Respiratory Disease 257

10.1	The Burden of Chronic Respiratory Disease in Rural Rwanda	257
10.1.1	The Impact of Biomass Fuels and Tuberculosis on Chronic Respiratory Disease	257
10.2	Integration of Chronic Respiratory Disease Management at Health-Center Level	258
10.2.1	Initial Evaluation for Chronic Respiratory Disease at Health-Center Level	258
10.2.2	Identification and Treatment of Emergency Conditions	260
10.2.3	Exclusion of Causes Other Than Asthma and COPD	260
10.3	Diagnosis and Initial Management of Chronic Respiratory Disease in Health Center Integrated Chronic Care Clinics	262
10.3.1	Step Therapy for Asthma or COPD at Health Centers	266
10.4	Follow-Up Management of Asthma	269
10.5	Bronchiectasis	271
	Chapter 10 References	273

EPILOGUE 277

APPENDIX A

Essential Equipment and Medicines 279

A.1	Essential Equipment	279
A.2	Essential Medicines	280
	Appendix A References	284

APPENDIX B

Cost Models 285

B.1	Summary of Operational Cost Models	285
B.2	Cardiomyopathy	286
B.2.1	Cost Inputs	286
B.2.2	Annual Regimen Costs Per Patient	286
B.2.3	Population Age Distribution and Case-Finding (Catchment Area: 350,000)	287
B.2.4	Total Marginal Costs Per Capita	287
B.3	Cardiac Surgery	287
B.3.1	Cost Inputs	287
B.3.1.1	Follow-Up Cost Inputs	287
B.3.1.2	Surgical Cost Inputs (At 300 Cases Per Year)	288

B.3.1.3	Average Cardiac Surgical Costs as a Function of the Number of Annual Operations	288
B.3.1.4	Regimen and Follow-Up Costs	289
B.3.2	Population Age Distribution and Case-Finding	289
B.3.3	Total Marginal Costs Per Capita (At 300 Cases Per Year)	289
B.4	Screening for HIV Nephropathy	289
B.4.1	Cost Inputs	289
B.4.2	Marginal Follow-Up Costs	289
B.4.3	Population Age Distribution and Case-Finding	290
B.4.4	Total Marginal Costs Per Capita	290
B.5	Diabetes	290
B.5.1	Cost Inputs	290
B.5.2	Annual Regimen Costs Per Patient	291
B.5.3	Population Age Distribution and Case-Finding	291
B.5.4	Total Marginal Costs Per Capita	292
B.6	Hypertension Cost Models	292
B.6.1	Cost Inputs	292
B.6.2	Annual Regimen Costs Per Patient	292
B.6.3	Population Age Distribution and Case-Finding	293
B.6.4	Total Marginal Costs Per Capita	293
B.7	Chronic Respiratory Disease Cost Models	294
B.7.1	Cost Inputs	294
B.7.2	Annual Regimen Costs Per Patient	294
B.7.3	Population Age Distribution and Case-Finding	294
B.7.4	Total Marginal Costs Per Capita	295

APPENDIX C

Indicators for Monitoring and Evaluation		297
C.1	Heart Failure and Post-Cardiac Surgery Follow-Up	297
C.2	Cardiac Surgical Referral and Case Selection	299
C.3	Renal Failure	300
C.4	Diabetes	301
C.5	Hypertension	303
C.6	Chronic Respiratory Disease	304

APPENDIX D

Forms		307
D.1	Intake Forms	307
D.2	Flowsheets	313
D.2.1	Sample Cover Sheet	313
D.2.2	Sample Events Flowsheet	314
D.2.3	Clinical Findings Flowsheet	315
D.2.3.1	Asthma	315

D.2.3.2	Diabetes	315
D.2.3.3	Post-Cardiac Surgery	316
D.2.3.4	Hypertension	316
D.2.3.5	Medication Flowsheet	316
D.2.4	Palliative Care Flowsheet	317
Appendix D References		318
APPENDIX E		
Common Normal Values		319
Appendix E References		323
INDEX		325

Figures

CHAPTER 1

FIGURE 1.1	The Long Tail of Endemic NCDs in Rwanda	4
FIGURE 1.2	Units of Planning for the Long-Tail Endemic NCDs	5
FIGURE 1.3	Integration of Human Resources for Chronic Care	9

CHAPTER 2

FIGURE 2.1	Diagram of Palliative Care throughout the Course of Illness and Bereavement (Adapted from WHO)	17
FIGURE 2.2	The WHO Three-Step Pain Ladder	23

CHAPTER 4

FIGURE 4.1	Distribution of Causes of Heart Failure in a Rwandan NCD clinic (n = 134)	44
FIGURE 4.2	Parasternal Long Axis View	49
FIGURE 4.3	Normal Parasternal Long Axis View on Echocardiography (Diastole, top; Systole, bottom)	50
FIGURE 4.4	Subcostal View	51
FIGURE 4.5	Subcostal View with Normal IVC (top) and Dilated IVC (bottom)	52
FIGURE 4.6	Cardiomyopathy in Parasternal Long Axis View (Diastole, top; Systole, bottom)	54
FIGURE 4.7	Mitral Stenosis in Diastole	55
FIGURE 4.8	Right Ventricular Enlargement (Parasternal Long View)	55
FIGURE 4.9	Pericardial Effusion (Parasternal View, top; Subcostal View, bottom)	57
FIGURE 4.10	ECG of Normal Rhythm (top) and Atrial Fibrillation (bottom)	109

CHAPTER 5

FIGURE 5.1	Indication for Cardiac Surgery between Nov. 2007 and Feb. 2010 (%)	120
FIGURE 5.2	Source of Cardiac Surgery in Rwanda between Nov. 2007 and Feb. 2010 (n)	120

CHAPTER 6

FIGURE 6.1	Normal Kidney Anatomy on Ultrasound	155
FIGURE 6.2	Ultrasound in Chronic Kidney Disease: Loss of Differentiation between Cortex and Medulla	156
FIGURE 6.3	Hydronephrosis on Ultrasound	157

CHAPTER 9

FIGURE 9.1	Progression from Pharyngitis to Rheumatic Fever	241
------------	---	-----

Tables

CHAPTER 1

TABLE 1.1	Burden of Non-Communicable Diseases in Rwanda Linked to Conditions of Poverty	2
TABLE 1.2	Leading Causes of Death and Disability in Rwanda in Disability-Adjusted Life Years (DALYs)	3
TABLE 1.3	Sample District Hospital–Based Clinician Schedule	9

CHAPTER 2

TABLE 2.1	Cost/Impact Matrix of Medical Interventions, with Examples	19
TABLE 2.2	Symptom Assessment Scale (Adapted from the African Palliative Outcomes Scale)	21
TABLE 2.3	Essential Medications for Pain Relief	26
TABLE 2.4	Essential Medications for Control of Nausea/Vomiting	28
TABLE 2.5	Essential Therapies for Treating Constipation	29
TABLE 2.6	Symptomatic Management of Diarrhea	30
TABLE 2.7	Management of Chronic Pruritus and Skin Care	31

CHAPTER 4

TABLE 4.1	Causes of Heart Failure Reported by Selected Echocardiographic Referral Centers in Sub-Saharan Africa	43
TABLE 4.2	Important Diagnostic Categories in Heart Failure	46
TABLE 4.3	Common Causes of Heart Failure by Age	47
TABLE 4.4	Physical Exam Findings in Classification of Heart Failure	48
TABLE 4.5	Echocardiographic Findings in Classification of Heart Failure	48
TABLE 4.6	Common Signs and Symptoms of Heart Failure (Usually Present in Addition to Shortness of Breath)	58
TABLE 4.7	New York Heart Association Heart Failure Classification	62
TABLE 4.8	Signs and Symptoms of Decompensated Heart Failure	63
TABLE 4.9	Reasons for Acute Decompensation in Patients with Heart Failure	64
TABLE 4.10	Volume Status Categories and Diuretic Adjustment	67
TABLE 4.11	Intravenous Furosemide Dosing	69
TABLE 4.12	Equivalent Oral and IV Furosemide Doses	70
TABLE 4.13	Oral Furosemide Dosing	70
TABLE 4.14	Other Oral Diuretic Dosing	71

TABLE 4.15	Etiology of Cardiomyopathy in Rwanda	72
TABLE 4.16	Mortality-Reducing Medications for Cardiomyopathy in Adults	75
TABLE 4.17	Medications for Cardiomyopathy in Children (≤ 40 kg)	76
TABLE 4.18	Adult Digoxin Dosing	83
TABLE 4.19	Antihypertensives for Hypertensive Heart Disease	86
TABLE 4.20	Medications to Reduce Heart Rate in Mitral Stenosis	90
TABLE 4.21	Medications for Valvular/Congenital Heart Disease	96
TABLE 4.22	Medications for Valvular/Congenital Heart Disease in Children (≤ 40 kg)	96
TABLE 4.23	Clinical Presentation of Right-Sided Heart Failure	98
TABLE 4.24	Causes of Right-Sided Heart Failure	99
TABLE 4.25	Treatment of Tuberculous Pericarditis	103
TABLE 4.26	Clinic Follow-Up Schedule for Heart Failure Patients	107

CHAPTER 5

TABLE 5.1	Typical Preoperative Evaluation for Cardiac Surgery	125
TABLE 5.2	Types of Valve Repairs	127
TABLE 5.3	Types of Replacement Heart Valves	129
TABLE 5.4	Empiric Antibiotic Treatments for Endocarditis	133
TABLE 5.5	Some Organism-Specific Treatments for Prosthetic Valve Endocarditis	135
TABLE 5.6	Common Drug Interactions with Warfarin	137
TABLE 5.7	Anticoagulation Agents and Indications	138
TABLE 5.8	Initial Outpatient Warfarin Dosing	139
TABLE 5.9	Therapies For Bridging Anticoagulation	140

CHAPTER 6

TABLE 6.1	Causes of End-Stage Renal Disease in Sub-Saharan Africa and the U.S.	147
TABLE 6.2	Relationship between Urine Dipstick and 24-hour Urine Protein Results	150
TABLE 6.3	Stages of Chronic Kidney Disease	151
TABLE 6.4	Normal Creatinine Ranges for Children by Age	152
TABLE 6.5	Ultrasound Findings Specific for Severe, Irreversible Kidney Disease	156
TABLE 6.6	Common Physical Symptoms in Advanced Chronic Kidney Disease and Their Treatment	160
TABLE 6.7	Common Psychological Symptoms in Advanced Chronic Kidney Disease and Their Treatment	162

CHAPTER 7

TABLE 7.1	Diabetes Diagnosis: Blood Sugar Measurement and Symptoms	170
TABLE 7.2	Danger Signs in Hyperglycemia	172
TABLE 7.3	Insulin Therapy of Patients with Hyperglycemia (≥ 250 mg/dL) and Danger Signs Awaiting Transfer	173
TABLE 7.4	Diagnosis and Treatment of Hypoglycemia	175
TABLE 7.5	Glucose Control Goals	176
TABLE 7.6	Oral Hypoglycemic Therapy	178
TABLE 7.7	Common Causes for Hyperglycemia in Patients on Insulin	179
TABLE 7.8	Indications for Insulin Therapy	180
TABLE 7.9	Properties of Insulin Available in Rwanda	183
TABLE 7.10	Insulin Regimens	184
TABLE 7.11	Example of Glucose Monitoring Chart	186
TABLE 7.12	Principles for Adjusting Insulin 70/30 (<i>Mixte</i>) or 2x/day NPH Regimens	189
TABLE 7.13	Principles for Adjusting Combined Basal (NPH) and Prandial (Regular Insulin) Regimens	189
TABLE 7.14	Example of Transitioning from 70/30 (<i>Insuline Mixtard</i>) to NPH/Regular (<i>Insuline Lente + Rapide</i>)	191
TABLE 7.15	Common Complications of Diabetes and Their Prevalence in Some African Cohorts	192

CHAPTER 8

TABLE 8.1	High-Risk Features in Hypertension	207
TABLE 8.2	Initiation of Hypertension Treatment According to Stage and Risk Factors	212
TABLE 8.3	Recommended Hypertension Medications and Dosing for Most Adult Patients	214
TABLE 8.4	Recommended Medications for Management of Hypertensive Emergency (Adult Dosing)	215
TABLE 8.5	Hypertension Medications and Dosing in Setting of Proteinuria or Mild Renal Failure (CKD 1-3, Creatinine 100–199 $\mu\text{mol/L}$)	216
TABLE 8.6	Recommended Hypertension Medications and Dosing in Setting of Severe Renal Failure (Creatinine ≥ 200 $\mu\text{mol/L}$)	217
TABLE 8.7	Causes of Secondary Hypertension	219
TABLE 8.8	Blood pressure ranges for children	223
TABLE 8.9	Recommended Medications and Dosing for Pediatric Patients For Hypertensive Emergency (BP \geq 99th percentile or \geq 95th percentile with symptoms)	224

TABLE 8.10	Recommended Medications and Dosing for Pediatric Patients with Chronic Hypertension (BP \geq 95th percentile)	226
TABLE 8.11	Recommended Hypertension Medications for Pediatric Patients with Renal Failure	228
TABLE 8.12	Hypertensive Disorders of Pregnancy	230
TABLE 8.13	Loading and Maintenance Dosing of Magnesium Sulfate in Eclampsia and Severe Preeclampsia (Adapted from IMPAC)	233
TABLE 8.14	Recommended Medications for Management of Hypertension in Severe Preeclampsia	234
TABLE 8.15	Recommended Hypertension Medications and Dosing in Pregnancy	235

CHAPTER 9

TABLE 9.1	Clinical Decision Rules for Treatment of Pharyngitis	242
TABLE 9.2	Antibiotic Regimens for Streptococcal Pharyngitis (Adults and Adolescents Dosing, Weight \geq 27 kg)	244
TABLE 9.3	Antibiotic Regimens for Streptococcal Pharyngitis (Pediatric Dosing, Weight \leq 27 kg)	244
TABLE 9.4	Modified Jones Criteria for High-Risk Groups	245
TABLE 9.5	Antibiotic Regimens for Secondary Prophylaxis of Rheumatic Fever	247
TABLE 9.6	Echocardiographic Prevalence of Definite and Possible RHD in School-Aged Children	249
TABLE 9.7	Echocardiographic Features of Left-Sided Heart Valves Thought Consistent with Rheumatic Heart Disease in High-Prevalence Settings by Three Sets of Criteria	250
TABLE 9.8	Proposed Criteria for Definite and Possible RHD	251

CHAPTER 10

TABLE 10.1	Evaluation of Asthma Attack Severity (Adapted from IUATLD Guidelines)	260
TABLE 10.2	Causes of Chronic Dyspnea or Chronic Cough (\geq 3 Weeks)	261
TABLE 10.3	Common Signs and Symptoms of Asthma	263
TABLE 10.4	Classification of Asthma Severity at Initial Visit	264
TABLE 10.5	Asthma Control Test	265
TABLE 10.6	Asthma Step Therapy	268
TABLE 10.7	Asthma Medication Dosing	269

APPENDIX E

TABLE E.1	Normal Vital Sign Values by Age	319
-----------	---------------------------------	-----

TABLE E.2	Blood pressure ranges by age for children	320
TABLE E.3	Peak Expiratory Flow Rates For Women (L/min)	321
TABLE E.4	Peak Expiratory Flow Rates Men (L/min)	321
TABLE E.5	Peak Expiratory Flow Rates For Children	322
TABLE E.6	Normal Lab Values	322
TABLE E.7	Normal Creatinine Values by Age	322

Protocols

CHAPTER 4

PROTOCOL 4.1	Initial Diagnosis and Management of Heart Failure	61
PROTOCOL 4.2	Management of Decompensated Heart Failure	65
PROTOCOL 4.3	Volume Status Assessment and Diuretic Adjustment	68
PROTOCOL 4.4	Cardiomyopathy Management	73
PROTOCOL 4.5	Beta-Blocker Titration in Cardiomyopathy	78
PROTOCOL 4.6	ACE-Inhibitor Titration and Use of Hydralazine/Isosorbide in Cardiomyopathy	80
PROTOCOL 4.7	Other Medication Needs for Cardiomyopathy Patients	82
PROTOCOL 4.8	Management of Suspected or Confirmed Hypertensive Heart Disease	85
PROTOCOL 4.9	Antihypertensive Management in Hypertensive Heart Disease	87
PROTOCOL 4.10	Assessment of Medication Contraindications and Side Effects in Management of Hypertensive Heart Disease	88
PROTOCOL 4.11	Management of Mitral Stenosis	89
PROTOCOL 4.12	Valvular or Congenital Heart Disease Management (Excluding Mitral Stenosis)	93
PROTOCOL 4.13	ACE-Inhibitor Titration for Valvular or Congenital Heart Disease Management (Excluding Mitral Stenosis)	95
PROTOCOL 4.14	Other Medications for Valvular or Congenital Heart Disease Management (Excluding Mitral Stenosis)	97
PROTOCOL 4.15	Management of Isolated Right-Sided Heart Failure	100
PROTOCOL 4.16	Fluid Status Management in Right-Sided Heart Failure	101
PROTOCOL 4.17	Diagnosis and Treatment of Tuberculosis Pericarditis	104
PROTOCOL 4.18	ACE-Inhibitor and Spironolactone Titration and Paracentesis for Isolated Right-Sided Heart Failure	105
PROTOCOL 4.19	Other Medication Needs in Isolated Right-Sided Heart Failure	106
PROTOCOL 4.20	Diagnosis and Management of Atrial Fibrillation in Adults	110
PROTOCOL 4.21	Palpitations in Adults	112

CHAPTER 5

PROTOCOL 5.1	Management of Fever in Patients with Prosthetic Heart Valves	134
PROTOCOL 5.2	Initiating Warfarin Therapy	141
PROTOCOL 5.3	Titrating Warfarin Therapy	143

CHAPTER 6

PROTOCOL 6.1	Initial Evaluation of Chronic Kidney Disease Stage 1 or 2	152
PROTOCOL 6.2	Initial Evaluation of Chronic Kidney Disease Stage 3, 4, and 5	154
PROTOCOL 6.3	Outpatient Management of Mild Hyperkalemia	159

CHAPTER 7

PROTOCOL 7.1	Diagnosis of Diabetes and Management of Hyperglycemia at Health-Center Level	171
PROTOCOL 7.2	Treatment of Diabetes with Oral Hypoglycemic Agents (in Adults)	177
PROTOCOL 7.3	Initiation and Adjustment of Insulin Regimens	181

CHAPTER 8

PROTOCOL 8.1	Initial Screening and Management of Hypertension in Adults in Acute Consultation Clinics	205
PROTOCOL 8.2	Initial Management of Newly Referred Adult Hypertension Cases in Health Center Integrated Chronic Care Clinics	208
PROTOCOL 8.3	Initial Diagnosis and Management of Suspected Secondary Hypertension in Adults (age ≥ 15)	218
PROTOCOL 8.4	Follow-Up Visit for Chronic Hypertension in Adults at Health Center Integrated Chronic Care Clinic	220
PROTOCOL 8.5	Initial Diagnosis and Management of Hypertension in Children in the Acute Care Clinic	222
PROTOCOL 8.6	Outpatient Follow-Up of Children with Hypertension	226
PROTOCOL 8.7	Management of Hypertension in Pregnancy	231

CHAPTER 9

PROTOCOL 9.1	Evaluation and Management of Pharyngitis	243
PROTOCOL 9.2	Screening for Rheumatic Heart Disease (and Other Conditions of School-Aged Children)	251

CHAPTER 10

PROTOCOL 10.1	Initial Management of Chronic Cough or Shortness of Breath at Health Center Acute Care Clinics	259
PROTOCOL 10.2	Initial Management of Asthma or COPD at Integrated Chronic Care Clinics	263
PROTOCOL 10.3	Follow-Up Management of Asthma or COPD at Health-Center Level	270